Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1173 • ACR Convergence 2024
Safety of Non-Exercise Rehabilitation Interventions for Adults with Rheumatoid Arthritis
Megna Mishra¹, Joshua Torrey², Bria Dunn² and Louise Thoma³, ¹UNC Health, Cary, ²University of North Carolina-Chapel Hill, Chapel Hill, ³University of North Carolina, Chapel Hill, NC
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory condition. Improved outcomes occur with early diagnosis, evaluation, and management. Management includes pharmacological, exercise, rehabilitation, diet,…
Abstract Number: 1333 • ACR Convergence 2024
Deciphering Variation in Real-World Early RA Outcomes: A Longitudinal Analysis of the Canadian Early Arthritis Cohort (CATCH) Study
Orit Schieir¹, Marie-France Valois², Gilles Boire³, Louis Bessette⁴, Carter Thorne⁵, Susan Bartlett², Glen Hazlewood⁶, Carol Hitchon⁷, Diane Tin⁵, Hugues Allard-Chamard⁸, Bindee Kuriya⁹, Janet Pope¹⁰ and Vivian Bykerk¹¹, and on behalf of CATCH Investigators, ¹McGill University, Montreal, QC, Canada, ²Centre for Outcomes Research & Eval, Montreal, QC, Canada, ³Retired, Sherbrooke, QC, Canada, ⁴University of Laval, Quebec City, QC, Canada, ⁵Newmarket Rheumatology Consultants, Newmarket, ON, Canada, ⁶University of Calgary, Calgary, AB, Canada, ⁷University of Manitoba, Winnipeg, MB, Canada, ⁸University of Sherbrooke, Sherbrooke, QC, Canada, ⁹University of Toronto, Toronto, Canada, ¹⁰University of Western Ontario, London, ON, Canada, ¹¹Hospital For Special Surgery, New York, NY
Background/Purpose: Despite advances in early RA diagnosis and therapies, treatment outcomes can still vary considerably. Our objective was to compare short and long-term disease control…
Abstract Number: 1349 • ACR Convergence 2024
Two Composite Cytokine Scores Predict Flare and Drug-free Remission in Patients with Rheumatoid Arthritis
Jasmine Sim¹, Nandhini Ramamoorthi², Fiona Rayner³, Abbie Degnan¹, Imogen Wilson¹, Julie Diboll¹, Anna Guttman⁴, Andrew Melville⁵, Nisha Rathore², Stefan Siebert⁵, Iain McInnes⁶, Carl Goodyear⁵, Catharien Hilkens¹, Andrew Filer⁷, Karim Raza⁷, Christopher Buckley⁸, Arthur Pratt¹, James Wason⁹, Amy Anderson¹, Michael Townsend², Kenneth Baker¹ and John Isaacs¹, ¹Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ²Genentech, South San Francisco, CA, ³Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, England, United Kingdom, ⁴Genentech, South San Franscisco, CA, ⁵School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ⁶University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, ⁷Rheumatology Research Group, Institute for Inflammation and Ageing, NIHR Birmingham Biomedical Research Center and Clinical Research Facility, University of Birmingham, Birmingham, United Kingdom, ⁸Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom, ⁹Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, United Kingdom
Background/Purpose: Recent studies show that half of patients with RA remission can stop conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) therapy to achieve drug-free remission (DFR),…
Abstract Number: 1365 • ACR Convergence 2024
Clinical Conditions Associated with Genetic Predisposition to Rheumatoid Arthritis in Real-World Settings
Hui Yu¹, Puran Nepal², Laura Daniel³, Marco Barbero Mota⁴, Gul Karakoc⁵, Maria Carpintero¹, C. Michael Stein⁶, Cecilia P. Chung¹, Yan Guo¹ and Vivian K. Kawai⁶, ¹University of MIami, Miami, FL, ²Vanderbilt University Medical Center, Vanderbilt, TN, ³University of Miami, Nashville, TN, ⁴Vanderbilt University, Nashville, TN, ⁵Vanderbilt University Medical Center, Mt. Pleasant, SC, ⁶Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Rheumatoid arthritis (RA) is a multisystem disease with a strong genetic component and multiple comorbidities. Genome wide association studies (GWAS) have identified single nucleotide…
Abstract Number: 1382 • ACR Convergence 2024
Synovial Expression Levels of PD-1, the Target of Rosnilimab, Correlate with Disease Activity and Persist Across Disease Stages and Lines of Therapy in Rheumatoid Arthritis
Yangsu Ren¹, Catherine Aversa¹, Myles Lewis², Cankut Cubuk³, Felice Rivellese⁴, Liliane Fossati-Jimack³, Pejman Soroosh¹, Amy Archer¹, Martin Dahl¹, Paul Lizzul¹, Cailin Sibley¹ and Costantino Pitzalis⁵, ¹AnaptysBio, San Diego, CA, ²Queen Mary University of London, London, United Kingdom, ³Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London and Barts NIHR BRC & NHS Trust, London, EC1M 6BQ, London, United Kingdom, ⁴Centre for Experimental Medicine & Rheumatology, Queen Mary University of London, London, United Kingdom, ⁵QMUL, Bromley Kent, United Kingdom
Background/Purpose: Despite multiple approved therapies in rheumatoid arthritis (RA), many patients do not achieve clinically meaningful responses, emphasizing the need for novel therapeutics with improved…
Abstract Number: 1398 • ACR Convergence 2024
Difficult to Treat Rheumatoid Arthritis Incidence and Risk Factors in the Early Arthritis UCLouvain Brussels Cohort
NATALUCCI Francesco¹, Clément triaille², SAPART Emilie³, DIERCKX Stéphanie⁴, VAN MULLEM Cécile³, de MONTJOYE Stéphanie³, SOKOLOVA Tatiana³, AVRAMOVSKA Aleksandra³ and DUREZ Patrick³, ¹Sapienza University of Roma, Rheumatology, Department of Clinical, Internistic, Anesthesiological and cardiovascular sciences, Roma, Italy, ²Pôle de pathologies rhumatismales systémiques et inflammatoires, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, Brussels, Belgium, ³Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Belgium, ⁴Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Bruxelles, Belgium
Background/Purpose: Over the past decades, the treatment of Rheumatoid Arthritis (RA) has significantly improved, making accessible therapeutic goals such as clinical and structural remission. However,…
Abstract Number: 1677 • ACR Convergence 2024
Safety and Efficacy of FNS007, a Non-T Cell Receptor Contacting Peptide, for Patients with Active Rheumatoid Arthritis: A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Trial
Ru Li¹, Xing Sun¹, Suping Niu², Xiaolin Sun¹, Guimin Zheng³, Meilu Liu³, Jiyang Lv⁴, Gengmin Zhou⁴, Gang Yuan⁵, Yujin Ye⁵, Shuang Wang⁵, Pingfei Fang⁶, Qi Tang⁶, Jin Kang⁶, Xiaoyue Li⁷, Chao Sun⁷, Song Zhang⁷, Yongjun Mei⁷, Jian Wang⁷, He Su⁷, Lijing Huang⁸, Chenhui Li⁸, Chao Liu⁸, Fengxiao Zhang³, Qingwen Wang⁴, Niansheng Yang⁵, Fen Li⁶, Linjie Chen⁷, Yi Fang² and Zhanguo Li⁹, ¹Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing, China, ²Clinical Trial Institution, Peking University People’s Hospital, Beijing, China, ³Department of Rheumatology and Immunology, Hebei General Hospital, Shijiazhuang, Hebei, China (People's Republic), ⁴Department of Rheumatism and Immunology, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China (People's Republic), ⁵Department of Rheumatology, First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China (People's Republic), ⁶Department of Rheumatology and Immunology, the Second Xiangya Hospital of Central South University, Changsha, Hunan, China (People's Republic), ⁷Department of Rheumatology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China, ⁸Hebei Fitness Biotechnology Limited Company, Shijiazhuang, Hebei, China (People's Republic), ⁹Peking univeristy people's hospital, Beijing, China
Background/Purpose: Long-term drug-free remission is an unmet need for the management of rheumatoid arthritis (RA), which might be achieved by restoring antigen-specific immune tolerance. Autoantigenic…
Abstract Number: 1785 • ACR Convergence 2024
Comparative Immuno-Metabolomics Shows Singular Changes in Systemic Lupus Erythematosus Metabolic Phenotype Induced by T-Cell Activation
Martin Stradner¹, Fernanda Monedeiro², Elmar Zuegner², Barbara Prietl³, Monika Oberhuber⁴, Michael Khalil⁵, Christoph Magnes², Hans-Peter Brezinsek¹, Angela Libiseller³ and Thomas Pieber³, ¹Div. of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ²Joanneum Research, Graz, Austria, ³Div. of Endocrinology, Medical University of Graz, Graz, Austria, ⁴CBmed, Graz, Austria, ⁵Dept. of Neurology, Medical University of Graz, Graz, Austria
Background/Purpose: Metabolic processes have a critical role in regulating immune cell function, therefore being relevant to understanding the pathogenesis and progression of autoimmune diseases. Here…
Abstract Number: 1894 • ACR Convergence 2024
Detection of Fibrotic Lung Changes and Bronchiectasis in RA Patients Screened for Lung Cancer with Low-dose CT Chest: Results from a Large Multi-hospital System
Gregory McDermott¹, Mark Hammer², Xiaosong Wang³, Misti Paudel⁴, Sung Hae Chang⁵, Pierre-Antoine Juge⁶, Qianru Zhang⁷, Jessica Lorusso⁸, Amie Samulyov⁸, Kathleen Vanni², Alene Saavedra², Emily Kowalski², Grace Qian³, Katarina Bade², Kevin Mueller², Jeffrey Sparks⁹ and Suzanne Byrne², ¹Brigham and Women's Hospital, Brookline, MA, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women’s Hospital, Boston, MA, ⁴Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ⁵Soonchunhyang University College of Medicine, Bongmyeong-dong, Dongnam-gu, Cheonan-si, South Korea, ⁶Departement of Rheumatology, AP-HP, Bichat Hospital, Boston, MA, ⁷Harard Medical School, Cambridge, ⁸Mass General Brigham, Boston, MA, ⁹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA
Background/Purpose: Cigarette smoking is a risk factor for both lung cancer and RA. Furthermore, RA is associated with pulmonary abnormalities including interstitial lung disease, bronchiectasis,…
Abstract Number: 1985 • ACR Convergence 2024
Underlying Autoimmune Disease Has Not Limited Immune Checkpoint Inhibitor Use or Increased Mortality Risk During Cancer Treatment of US Veterans
Madeline O’Sullivan¹, grant Cannon², Sauer brian³, Jorge Rojas⁴, Gary Kunkel⁵, Jessica A Walsh⁶, Punyasha Roul⁷, shardool Patel¹, Joshua Baker⁸, Bryant England⁹ and Tawnie Braaten¹, ¹University of Utah, Salt Lake City, UT, ²University of Utah and Salt Lake City VA, Salt Lake City, UT, ³Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁴Seattle VA, Mexico, Mexico, ⁵University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁶Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ⁷UNMC, Omaha, NE, ⁸University of Pennsylvania, Philadelphia, PA, ⁹University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Immune checkpoint inhibitors (ICIs) can cause a variety of immune-related adverse events (irAEs) affecting multiple organ systems, and patients with pre-existing autoimmune disease (AID)…
Abstract Number: 2212 • ACR Convergence 2024
Seropositive Arthralgias: A Comprehensive Analysis of the Reuma-Check Cohort
Rodrigo Garcia Salinas¹, Felicia Almada², Gisel Reyes-Jara², Ronald Perez-Andocillas² and Sebastian Magri³, ¹Hospital Italiano La Plata, La Plata, Argentina, ²Hospital Italiano de La Plata, La Plata, Argentina, ³Hospital Italiano La Plata, Melchor Romero, Argentina
Background/Purpose: To estimate the frequency of seropositive arthralgia (SA) in a large cohort of patients evaluated for arthralgia in Reuma-check program. To compare the features…
Abstract Number: 2230 • ACR Convergence 2024
Relationship Between the Complement System and Serum Lipid Profile in Patients with Rheumatoid Arthritis
Maria Garcia-Gonzalez¹, Fuensanta Gomez-Bernal², Juan Carlos Quevedo-Abeledo³, Miguel Angel Gonzalez-Gay⁴ and ivan Ferraz-Amaro⁵, ¹Hospital Universitario de Canarias, SC Tenerife, Canarias, Spain, ²Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, ³Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de GC, Canarias, Spain, ⁴University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, ⁵Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain
Background/Purpose: The complement system has been linked to the etiopathogenesis of rheumatoid arthritis (RA). Patients with RA exhibit a dysregulated profile of lipid molecules, which…
Abstract Number: 2246 • ACR Convergence 2024
Safety and Efficacy of Cannabidiol in Rheumatoid Arthritis Patients: A Phase 1B Pilot Randomized Placebo Controlled Trial
Veena Ranganath¹, Holly Wilhalme², Nicolette Morris³, Jenny Brook², Mihaela Taylor¹, Howard Yang¹, Tanaz Kermani⁴, Thanda Aung², Brian Skaggs¹, David Elashoff⁵ and ziva Cooper⁶, ¹UCLA, Los Angeles, CA, ²UCLA, Los Angeles, ³The University of Queensland Medical School, Ochsner Clinical School, New Orleans, LA, ⁴University of California Los Angeles, Santa Monica, CA, ⁵UCLA Department of Medicine Statistics Core, Los Angeles, ⁶UCLA Center for Cannabis and Cannabinoids, Semel Institute for Neuroscience & Human Behavior, Dept of Psychiatry and Biobehavioral Sciences, Dept of Anesthesiology and Perioperative Medicine, Los Angeles
Background/Purpose: There is no cure for rheumatoid arthritis (RA) and remission rates vary greatly 10-60%; thus, there is an unmet need for safe adjunctive therapeutic…
Abstract Number: 2267 • ACR Convergence 2024
A Novel Blood-based Assay That Predicts Clinical Response to TNFα Inhibitors or Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis
Maggie Louie¹, Signe Fransen², Katherine Dilger¹, Kevin Lai¹, Diana Abdueva³, David Chernoff⁴ and Jeffrey Curtis⁵, ¹Aqtual Inc, Hayward, CA, ²Aqtual Inc., sf, CA, ³Aqtual Inc., Hayward, CA, ⁴SetPoint Medical, Sausalito, CA, ⁵University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Current rheumatoid arthritis (RA) treatments, including TNFa inhibitors (TNFi) and JAK inhibitors (JAKi), have transformed the management of RA by controlling symptoms and slowing…
Abstract Number: 2284 • ACR Convergence 2024
Real-World Evidence of the Antifibrotic Nintedanib in Rheumatoid Arthritis-Interstitial Lung Disease. National Multicenter Study of 74 Patients from Clinical Practice
Belén Atienza-Mateo¹, Ana Serrano-Combarro², Jesús Loarce³, Nuria Vegas Revenga⁴, María Martín López⁵, Santos Castañeda⁶, Rafael Benito Melero-Gonzalez⁷, Natalia Mena Vázquez⁸, Carmen Carrasco-Cubero⁹, Carolina Díez Morrondo¹⁰, David Castro-Corredor¹¹, Tomás Vázquez Rodríguez¹², Andrea García-Valle¹³, Gema Bonilla¹⁴, Marina Rodriguez¹⁵, Ignacio Brana Abascal¹⁶, Sara María Rojas Herrera¹⁷, Juan Camilo Sarmiento-Monroy¹⁸, Pablo Andújar-Brazal¹⁹, Diego Ferrer²⁰ and Ricardo Blanco-Alonso²¹, and Rest of the Members of the Spanish Collaborative Group of Antifibrotics in Interstitial Lung Disease Associated with Rheumatoid Arthritis, ¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, ³Ramón y Cajal University Hospital, Madrid, Madrid, Spain, ⁴Hospital Galdakao- Usansolo, Galdakao, Spain, ⁵General University Hospital of Ciudad Real, Ciudad de México, Spain, ⁶Hospital Universitario de la Princesa, Madrid, Spain, ⁷CHU Ourense, O Carballino, Spain, ⁸IBIMA, Málaga, Andalucia, Spain, ⁹Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, ¹⁰Complejo Asistencial Universitario de Leon, Leon, ¹¹General University Hospital of Ciudad Real, Santa Cruz de Mudela (Ciudad Real), Spain, ¹²Complejo Hospitalario Universitario de Ferrol, Ferrol, Spain, ¹³Hospital General Río Carrión, Palencia, Spain, ¹⁴H. Universitario La Paz, Madrid, Spain, ¹⁵Hospital Clínico Universitario de Santiago, La Coruna, Spain, ¹⁶Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain, ¹⁷Hospital de Mérida, Badajoz, Spain, ¹⁸Hospital Clínic Barcelona, Barcelona, Spain, ¹⁹Hospital Universitario Doctor Peset, Valencia, Spain, ²⁰Division of Pneumology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) is a serious complication of rheumatoid arthritis (RA), with a prevalence that ranges from 7 to 30% patients with RA,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].